Materias dentro de su búsqueda.
Mostrando 34,601 - 34,620 Resultados de 34,656 Para Buscar 'biguru~', tiempo de consulta: 1.72s Limitar resultados
  1. 34601
    “…The case also places emphasis on the role of FDG-PET/CT as a diagnostic and prognostic tool. SUV-max figures aid interpretation but should always be compared with a physiological baseline as patient-related factors can vary. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    4. A paraneoplastic case of dermatomyositis
  2. 34602
    “…At OHSU, the percentage of RPGs held by women physician-scientists is below the national figure. Funding sources for physician-scientists at OHSU were more diverse than for Ph.D. scientists, and physician-scientists comprise the majority of Principal Investigators on clinical trials. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    2237 From bedside to benchmarks: A physician-scientist workforce dashboard for biomedical research institutions
  3. 34603
    “…Additional data collection and analyses are ongoing. [Figure: see text] DISCLOSURES: Lynch:Bayer: Research Funding; Rhizen Pharmaceuticals: Research Funding; Incyte: Research Funding; TG Therapeutics: Research Funding; Takeda: Research Funding; Juno Therpeutics: Research Funding; Genentech: Research Funding; MorphoSys: Consultancy; Cyteir: Research Funding. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Severity of Sars-Cov-2 Infection in Patients with Hematologic Malignancies: A COVID-19 and Cancer Consortium (CCC19) Registry Analysis
  4. 34604
    “…The rapid reduction of anti-SARS-CoV-2 antibodies in our cohort reveals a time pattern of reduction, although we do not know if neutralizing antibodies share the same trend or if this reduction affects the host immunity against SARS-CoV-2. [Figure: see text] DISCLOSURES: Terpos:Amgen: Honoraria, Research Funding; BMS: Honoraria; Genesis pharma SA: Honoraria, Other: travel expenses , Research Funding; Janssen: Honoraria, Research Funding; Takeda: Honoraria, Other: travel expenses , Research Funding; Celgene: Honoraria; Sanofi: Honoraria. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Rapid Reduction of Anti-Sars-Cov-2 Antibodies in Convalescent Plasma Donors; Results of a Phase 2 Clinical Study
  5. 34605
    “…The Registry has been expanded to include non-malignant hematologic diseases, and the Registry will continue to accumulate data as a resource for the hematology community. [Figure: see text] DISCLOSURES: Wood:Pfizer: Research Funding; Teladoc/Best Doctors: Consultancy; ASH Research Collaborative: Honoraria. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Outcomes of Patients with Hematologic Malignancies and COVID-19 Infection: A Report from the ASH Research Collaborative Data Hub
  6. 34606
    “…[Image: see text] In this figure, each nursing home is represented by a circle. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    5. The PROTECT Trial: A Cluster Randomized Clinical Trial of Universal Decolonization with Chlorhexidine and Nasal Povidone Iodine Versus Standard of Care for Prevention of Infections and Hospital Readmissions among Nursing Home Residents
  7. 34607
    “…The full protocol can be accessed via the trial's website. [Figure: see text] DISCLOSURES: Milojkovic:  Novartis: Honoraria, Speakers Bureau; Incyte: Honoraria, Speakers Bureau; Bristol-Myers Squibb: Honoraria, Speakers Bureau; Pfizer: Honoraria, Speakers Bureau. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Multi-Arm Trial of Inflammatory Signal Inhibitors (MATIS) for Hospitalised Patients with Mild or Moderate COVID-19 Pneumonia: A Structured Summary of a Study Protocol for a Randomised Controlled Trial
  8. 34608
    “…Patients who achieve CR/CRi have good short-term outcomes and are able to proceed to a potentially curative allogeneic stem cell transplant. [Figure: see text] DISCLOSURES: Belsham:  Celgene: Other: meeting attendance; Abbvie: Other: meeting attendance. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Gilteritinib for Relapsed Acute Myeloid Leukaemia with FLT3 Mutation during the COVID-19 Pandemic: Real World Experience from the UK National Health Service
  9. 34609
    “…Since these differences may be a surrogate for a higher disease burden, it will be important to compare outcomes at longer time points. [Figure: see text] DISCLOSURES: DeAngelo:  Pfizer: Consultancy; Novartis: Consultancy, Research Funding; Jazz: Consultancy; Incyte: Consultancy; Forty-Seven: Consultancy; Autolus: Consultancy; Amgen: Consultancy; Agios: Consultancy; Takeda: Consultancy; Glycomimetrics: Research Funding; Blueprint: Research Funding; Abbvie: Research Funding; Servier: Consultancy. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Clinical Characteristics and Outcomes of Patients with Newly Diagnosed De Novo Acute Myeloid Leukemia (AML) during the COVID-19 Pandemic
  10. 34610
    “…We thereby suggest that the pandemic had a great impact not only on the conduct of the study but also on patients' perception of their disease, if not properly reassured. [Figure: see text] DISCLOSURES: Molica:  Astrazeneca: Honoraria; Abbvie: Consultancy, Honoraria; Janssen: Consultancy, Honoraria. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    COVID-19 Pandemic Impact on Chronic Lymphocytic Leukemia (CLL) Patients' Preferences Towards Therapies: The Italian Experience (CHOICE Study)
  11. 34611
    “…In conclusion, in clinical practice, IL-6 inhibition should be individualized based on pathophysiology and regular CRP monitoring. [Figure: see text] DISCLOSURES: Rossi:  E-SANA Inc: Other: Co-founder of E-SANA Inc ; EUSA Pharma: Consultancy; LEO Pharma: Consultancy; NPO Petrovax Pharm: Consultancy. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Association between Insufficient Interleukin-6 (IL-6) Inhibition and Worsening Outcomes in COVID-19 and Idiopathic Multicentric Castleman Disease (iMCD), and a Mathematical Model to Predict Optimal Dosing to Completely Block IL-6 Activity
  12. 34612
    “…For such patients, an anamnestic dosing strategy could be considered, especially after completion of anticlonal therapy. [Figure: see text] DISCLOSURES: Kastritis:  Genesis Pharma: Honoraria; Janssen: Consultancy, Honoraria, Research Funding; Takeda: Honoraria; Pfizer: Consultancy, Honoraria, Research Funding; Amgen: Consultancy, Honoraria, Research Funding. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Antibody Response after Vaccination for Sars-Cov-2 in Patients with AL Amyloidosis and the Impact of Therapy
  13. 34613
    “…In this context, additional booster doses may be considered for MM patients with poor humoral response after the BNT162b2 vaccine. [Figure: see text] DISCLOSURES: Gavriatopoulou:  Genesis: Honoraria; Karyopharm: Honoraria; Takeda: Honoraria; Janssen: Honoraria; Sanofi: Honoraria; GSK: Honoraria; Amgen: Honoraria. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Patients with Multiple Myeloma and Prior COVID-19 Have Superior Antibody Responses Against Sars-Cov-2 Compared with Fully Vaccinated Myeloma Patients with the BNT162b2 Vaccine
  14. 34614
    “…Multivariate analysis of this data will be completed in advance of the meeting. [Figure: see text] DISCLOSURES: Olszewski:  Celldex Therapeutics: Research Funding; PrecisionBio: Research Funding; TG Therapeutics: Research Funding; Acrotech Pharma: Research Funding; Genentech, Inc.: Research Funding; Genmab: Research Funding. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A Multi-Center Retrospective Review of COVID-19 Outcomes in Patients with Lymphoid Malignancy
  15. 34615
    “…Novel immunization strategies (active or passive) are urgently needed in this population. [Figure: see text] DISCLOSURES: Gritsman:  iOnctura: Research Funding. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Seroconversion Rates after COVID-19 Vaccination Amongst Patients with Hematologic Malignancies: Results of a Rapid Vaccination and Evaluation Program in a Minority Rich, Ethnically Diverse Inner City Cohort
  16. 34616
    por Li, Li, Feng, Qing
    Publicado 2022
    “…It can be further seen from Figure 5 that both conscious and unconscious attention dispersion can effectively improve the positive mood of non depressed people. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    INFLUENCING FACTORS AND COUNTERMEASURES OF THE CHANGE OF POPULATION DEPENDENCY RATIO IN YUNNAN PROVINCE FROM THE PERSPECTIVE OF EMOTIONAL REGULATION OF POSITIVE PSYCHOLOGY
  17. 34617
    “…The tibial slope was corrected using a supra-tubercle anterior closing wedge (ACW) proximal tibial osteotomy (PTO) in 16 patients (Neyret et al 2000) and with a complete tibial tubercle osteotomy (TTO) in one case (Bertrand et al 2014) (Figure 1). Osteotomies were stabilized using Richards regular fixation staples(®) (Smith & Nephew) or the TOMOFIX(®) osteotomy system (DePuy Synthes) was used. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Poster 214: Posterior Tibial Slope Reducing Osteotomy in Complex Revision Anterior Cruciate Ligament Reconstruction
  18. 34618
    “…Overall percent probabilities of PK-PD target attainment were > 99.9%. [Figure: see text] [Figure: see text] CONCLUSION: Results of PK-PD target attainment analyses provided support for ceftobiprole dosing regimens for patients with SAB with 500 mg IV every 6 hours on Days 1 to 8 and every 8 hours from Day 9. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    2531. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Ceftobiprole Dosing Regimens for Patients with Staphylococcus aureus Bacteremia (SAB)
  19. 34619
    “…B-Nicolae Paulescu publicly manifested his Judeophobic ideology on multiple occasions in academic and political interventions and in publications and participated with other figures from the Romanian intellectual sphere in the founding of the Uniunea Național Crestinǎ (UNC, National Christian Union) in 1922 and of the Liga Apǎrǎrii Național Cresține (LANC, League for Christian National Defense) in 1923, antisemitic far-right political parties, associated with an irrational Christian orthodoxy and hatred of Jews. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    On the occasion of the centennial of the Nobel Prize in Physiology or Medicine, 1923: Nicolae C. Paulescu—between scientific creativity and political fanatism
  20. 34620
    “…FTB achieved composite success in 8/16 patients (clinical success in 13/16 patients) with P. aeruginosa overall; from 1 to 5 patients in the FTB group had P. aeruginosa in defined resistance categories. [Figure: see text] CONCLUSION: FTB demonstrated efficacy in cUTI patients infected with cefepime-, multidrug-, and carbapenem-resistant pathogens and pathogens carrying ESBL, AmpC, and carbapenemase genes. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    2523. Outcomes by Resistance Phenotype and Genotype among Baseline Pathogen in Patients with Complicated Urinary Tract Infection (cUTI) in the Phase 3 CERTAIN-1 Study
Herramientas de búsqueda: RSS